Ifosfamide

Generic Name
Ifosfamide
Brand Names
Ifex
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
3778-73-2
Unique Ingredient Identifier
UM20QQM95Y
Background

Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication

Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...

Associated Conditions
Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
Associated Therapies
-

S9624 Ifosfamide in Treating Patients With Meningeal Tumors

First Posted Date
2003-01-27
Last Posted Date
2013-11-08
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
7
Registration Number
NCT00003292
Locations
🇵🇷

San Juan City Hospital, San Juan, Puerto Rico

🇺🇸

CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States

🇺🇸

Mercy Medical Center, Des Moines, Iowa, United States

and more 67 locations

Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

First Posted Date
2003-01-27
Last Posted Date
2013-07-10
Lead Sponsor
Tulane University Health Sciences Center
Registration Number
NCT00028860
Locations
🇺🇸

Tulane Cancer Center at Tulane University Hospital and Clinic, New Orleans, Louisiana, United States

Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus

Phase 3
Completed
Conditions
First Posted Date
2003-01-27
Last Posted Date
2013-07-09
Lead Sponsor
Gynecologic Oncology Group
Target Recruit Count
166
Registration Number
NCT00003128
Locations
🇺🇸

CCOP - Carle Cancer Center, Urbana, Illinois, United States

🇺🇸

CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States

🇺🇸

Tufts - New England Medical Center, Boston, Massachusetts, United States

and more 14 locations

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
First Posted Date
2003-01-27
Last Posted Date
2013-07-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00002982
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer

Phase 2
Completed
Conditions
First Posted Date
2003-01-27
Last Posted Date
2013-07-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
40
Registration Number
NCT00002684
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer

First Posted Date
2003-01-27
Last Posted Date
2013-07-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
30
Registration Number
NCT00003105
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma

First Posted Date
2003-01-27
Last Posted Date
2013-06-27
Lead Sponsor
Radiation Therapy Oncology Group
Registration Number
NCT00017160
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

🇺🇸

Valley Hospital, Ridgewood, New Jersey, United States

and more 232 locations

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer

First Posted Date
2003-01-27
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
222
Registration Number
NCT00003941
Locations
🇧🇪

Institut Jules Bordet, Brussels (Bruxelles), Belgium

🇩🇪

St. Johannes Hospital - Medical Klinik II, Duisburg, Germany

🇩🇪

Universitaetsklinikum Halle, Halle (Saale), Germany

and more 34 locations
© Copyright 2024. All Rights Reserved by MedPath